| Literature DB >> 29198342 |
Francesca De Felice1, Marco de Vincentiis2, Valentino Valentini3, Daniela Musio4, Silvia Mezi5, Luigi Lo Mele6, Marco Della Monaca3, Vittorio D'Aguanno2, Valentina Terenzi3, Martina Di Brino6, Edoardo Brauner3, Nadia Bulzonetti4, Gianluca Tenore3, Giulia Pomati5, Andrea Cassoni3, Mario Tombolini2, Andrea Battisti3, Antonio Greco2, Giorgio Pompa3, Antonio Minni2, Umberto Romeo3, Enrico Cortesi5, Antonella Polimeni3, Vincenzo Tombolini4.
Abstract
Salivary gland malignant tumor (SGMT) is a malignant disease requiring multidisciplinary approach. The rare incidence and the consequent lack of robust evidence-based medicine has called for a comprehensive update to draw recommendations for clinical practice. This paper is a summary of the XXX Head and Neck Unit guidelines regarding the management of SGMT. Recommendations include the indications for exclusive and adjuvant therapy, as well as metastatic management, for both major and minor SGMT.Entities:
Keywords: Chemotherapy; Head and neck cancer; Management; Outcomes; Parotid; Radiotherapy; Salivary gland; Surgery
Mesh：
Year: 2017 PMID： 29198342 DOI： 10.1016/j.critrevonc.2017.10.010
Source DB: PubMed Journal: Crit Rev Oncol Hematol ISSN： 1040-8428 Impact factor: 6.312